• Broad-Spectrum Bivalent mRNA Vaccine Neutralizes SARS-CoV-2

  2026-05-17

  This study presents a preclinical evaluation of the bivalent mRNA vaccine RQ3025, designed to induce robust neutralizing immunity against a wide range of SARS-CoV-2 variants. The vaccine’s dual-targeting approach and demonstrated effectiveness in multiple animal models highlight its potential to address immune escape by emerging variants and support future translational research.

• ELP-Mediated p21 Peptide Delivery Inhibits Glioblastoma Grow

  2026-05-16

  This study demonstrates that an elastin-like polypeptide (ELP)-conjugated, p21-derived peptide can be efficiently delivered into glioblastoma cells, resulting in potent suppression of cell proliferation via cytostatic mechanisms. The approach addresses delivery and stability barriers in peptide-based therapies, marking a significant advance in targeting cell-cycle dysregulation in aggressive brain tumors.

• HPF and the Future of Highly Reactive Oxygen Species Detecti

  2026-05-15

  This thought-leadership article explores the mechanistic selectivity and translational utility of HPF (hydroxyphenyl fluorescein) for detecting highly reactive oxygen species (hROS) in advanced cancer phototherapy and cell biology. Integrating recent breakthroughs in multimodal phototherapeutic agents, it provides strategic guidance for researchers seeking precision in oxidative stress visualization and highlights APExBIO's HPF as the gold standard for specificity, reliability, and workflow optimization.

• Pam3CSK4: TLR1/2 Agonist Workflows for Immune Activation

  2026-05-15

  Pam3CSK4 enables precise TLR1/2 pathway activation, powering advanced modeling of immune cell responses and allergy inflammation. Robust, reproducible workflows and troubleshooting strategies maximize translational impact for immunology and neuro-immune research.

• Ionomycin Calcium Salt (SKU B5165): Data-Driven Solutions fo

  2026-05-14

  This article addresses key laboratory challenges in cell viability and apoptosis assays, offering scenario-driven guidance for using Ionomycin calcium salt (SKU B5165). By integrating peer-reviewed data and best practices, it demonstrates how APExBIO’s product ensures reproducibility and assay sensitivity in research workflows.

• Molidustat (BAY85-3934): A Mechanistic Leap in Renal Anemia

  2026-05-14

  This thought-leadership article explores the mechanistic underpinnings and translational impact of Molidustat (BAY85-3934), a next-generation HIF prolyl hydroxylase inhibitor. We synthesize evidence from recent cardiovascular apoptosis research, highlight the unique performance of Molidustat in chronic kidney disease anemia, and deliver strategic guidance for experimentalists seeking to harness endogenous erythropoietin stimulation. The discussion addresses protocol optimization, competitive positioning, and future directions, while contextualizing new cross-domain insights in hypoxia signaling.

• Moesin as a Biomarker of Endothelial Injury in Sepsis: Insig

  2026-05-13

  This article reviews recent evidence supporting moesin as a novel biomarker of endothelial injury in sepsis, highlighting its mechanistic role in vascular dysfunction and potential for severity assessment. The findings provide a rigorous platform for translational research into endothelial regulation, pH homeostasis, and related therapeutic strategies.

• Mechanisms of Propranolol Action in Essential Tremor: TMS In

  2026-05-13

  This study elucidates the neurophysiological mechanisms underlying propranolol’s therapeutic effects in essential tremor (ET) using advanced transcranial magnetic stimulation (TMS) paradigms. The findings provide direct evidence for central and peripheral pathways involved in tremor suppression, refining our understanding of this non-selective β-adrenergic receptor blocker’s multi-modal action.

• BI 2536 and PLK1: Transforming Mitotic Checkpoint Research

  2026-05-12

  This thought-leadership article dissects the mechanistic and translational impact of PLK1 inhibition using BI 2536, exploring new frontiers in mitotic checkpoint regulation and providing actionable strategies for researchers in cancer biology.

• Reversine: Precision Aurora Kinase Inhibitor for Cancer Rese

  2026-05-12

  Reversine, a potent Aurora kinase inhibitor from APExBIO, empowers researchers to dissect mitotic checkpoints and cell fate with nanomolar precision. This guide translates recent breakthroughs in gastruloid modeling and cancer biology into actionable workflows, troubleshooting steps, and comparative insights for advanced applications.

• Mianserin HCl: Applied 5-HT2 Receptor Antagonist Workflows

  2026-05-11

  Leverage Mianserin HCl as a robust 5-HT2 receptor antagonist for precise dissection of serotonergic pathways and novel antipathogenic research. This guide translates cutting-edge findings into stepwise protocols, highlights critical experimental pitfalls, and contextualizes APExBIO’s reagent within the latest comparative insights.

• IRG1-Itaconic Acid Axis Modulates TBK1-Driven Type I IFN Res

  2026-05-11

  This study uncovers a feedback mechanism in which IRG1-derived itaconic acid alkylates TBK1 at Cys605, disrupting its dimerization and restraining excessive type I interferon (IFN-I) responses. The development of novel itaconic acid-based TBK1 inhibitors highlights new therapeutic potential for diseases linked to IFN-I hyperactivation.

• Applied Uses of TNF-alpha Recombinant Murine Protein in Apop

  2026-05-10

  APExBIO’s TNF-alpha recombinant murine protein empowers advanced dissection of apoptotic and inflammatory signaling in cell culture, thanks to unrivaled potency and batch consistency. Integrating frontier insights from RNA Pol II signaling, this article reveals how optimized protocols can unlock new mechanistic clarity and reproducibility in apoptosis research.

• Tacalcitol Monohydrate: Synthetic Analog of Vitamin D3 in Tr

  2026-05-09

  Tacalcitol monohydrate, a potent synthetic analog of vitamin D3, enables both precise NGF induction in keratinocytes and robust enhancement of chemotherapeutic efficacy in colorectal cancer models. With low calcemic toxicity and reproducible topical or in vitro workflows, it stands out as a translational tool for dermatology and oncology alike.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-05-09

  0.4% Trypan Blue Solution enables rapid, direct assessment of cell viability by distinguishing live from dead cells based on membrane integrity. It is best suited for cell culture workflows, cytotoxicity assays, and viability checks where precise live/dead discrimination is required. This reagent is not intended for diagnostic or clinical applications.

408 records 15/28 page Previous Next First page 上5页 1112131415 下5页 Last page